Literature DB >> 20875353

Trends in in-hospital mortality and six-month outcomes in patients with a first acute myocardial infarction. Change over the last decade.

Cosme García-García1, Gines Sanz, Vicente Valle, Lluís Molina, Joan Sala, Isaac Subirana, Helena Martí, Jaume Marrugat, Jordi Bruguera, Rafel Masià, Roberto Elosua.   

Abstract

INTRODUCTION AND
OBJECTIVES: Treatment of acute myocardial infarction (AMI) has changed considerably in recent years. The objective of this study was to investigate differences in in-hospital mortality and 6-month outcomes after a first AMI between patients who participated in two trials, in 1992-1994 and 2001-2003, respectively.
METHODS: The study involved 1440 consecutive patients with a first AMI who were admitted to four university hospitals during 1992-1994 (the RESCATE-I trial) and 1288 with a first AMI who met the same diagnostic criteria and who were admitted to the same hospitals during 2001-2003 (the RESCATE-II trial). Patient management, in-hospital mortality and 6-month prognosis and outcomes were compared between the two trials.
RESULTS: Reperfusion therapy was carried out in 60.7% of patients in the first trial and in 72.6% in the second (P< .001). In the RESCATE-II trial, the median door-to-needle time was shorter (41 min vs. 93 min; P< .001) and patients more frequently underwent coronary angiography (65.2% vs. 28.1%; P< .001) and revascularization (34.9% vs. 8.1%; P< .001). In addition, in-hospital mortality was lower in RESCATE-II (7.5% vs. 10.9%; P< .001). After adjustment for age, sex, comorbidity, AMI severity and reperfusion therapy, the odds ratio for in-hospital mortality in RESCATE-II compared with the first trial was 0.52 (95% confidence interval, 0.31-0.86). In addition, mortality (1.4% vs. 3.6%; P=.001) and readmissions at 6 months were also lower in RESCATE-II.
CONCLUSIONS: Both in-hospital and 6-month mortality in patients with a first AMI decreased during the last decade, probably due to more frequent reperfusion and revascularization therapy and better medical treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20875353     DOI: 10.1016/s1885-5857(10)70227-9

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  4 in total

1.  Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment.

Authors:  A Ramírez de Arellano; A Coca; M de la Figuera; C Rubio-Terrés; D Rubio-Rodríguez; A Gracia; A Boldeanu; J Puig-Gilberte; E Salas
Journal:  Appl Health Econ Health Policy       Date:  2013-10       Impact factor: 2.561

2.  Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion.

Authors:  Núria Ribas; Cosme García-García; Oona Meroño; Lluís Recasens; Silvia Pérez-Fernández; Víctor Bazán; Neus Salvatella; Julio Martí-Almor; Jordi Bruguera; Roberto Elosua
Journal:  BMC Cardiovasc Disord       Date:  2017-02-07       Impact factor: 2.298

3.  In-hospital prognosis and long-term mortality of STEMI in a reperfusion network. "Head to head" analisys: invasive reperfusion vs optimal medical therapy.

Authors:  C García-García; N Ribas; L L Recasens; O Meroño; I Subirana; A Fernández; A Pérez; F Miranda; H Tizón-Marcos; J Martí-Almor; J Bruguera; R Elosua
Journal:  BMC Cardiovasc Disord       Date:  2017-05-26       Impact factor: 2.298

4.  Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Min Li; Chengyu Li; Shiqi Chen; Yang Sun; Jiayuan Hu; Chen Zhao; Ruijin Qiu; Xiaoyu Zhang; Qin Zhang; Guihua Tian; Hongcai Shang
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.